Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
ENVISAGE-TAVI AF: Edoxaban noninferior to warfarin for adverse events after TAVI
Author(s): George D Dangas Added: 2 years ago
In this short video, Dr George Dangas (Mount Sinai Hospital, New York, NY, US) shares the findings from the ENVISAGE-TAVI AF hot line trial presented at ESC Congress 2021. ENVISAGE-TAVI AF (Daiichi-Sankyo) compared the safety and efficacy of the DOAC edoxaban with VKAs (warfarin and its analogues) in atrial fibrillation patients with an indication for oral anticoagulation after successful TAVI. … View more

Anticoagulation

Electrophysiology & Arrhythmia
A John Camm
Research Area(s) / Expertise: Job title: Professor of Clinical Cardiology
John Camm is British Heart Foundation Professor of Clinical Cardiology (Emeritus) at St George’s University of London, London, UK. His interests include cardiac arrhythmias, atrial fibrillation, stroke prevention, and anticoagulation. Prof Camm is Editor of the European Society of Cardiology Textbook of Cardiovascular Medicine and ESC CardioMed, Electrophysiology of the Heart, Clinical… View more
Stefan James
Job title: Professor of Cardiology
Prof Stefan James is Professor of Cardiology at Uppsala University, Scientific Director of Uppsala Clinical Research Center and a senior Interventional Cardiologist at Uppsala University Hospital in Sweden. He is the president of the Swedish society of Cardiology and a Fellow of the ESC.He graduated from Uppsala University Medical School and completed specialist training in Uppsala. He has… View more
STOPDAPT-2 ACT: 1-month DAPT Followed by Clopidogrel Monotherapy in ACS
Author(s): Hirotoshi Watanabe Added: 2 years ago
Dr. Hirotoshi Watanabe (Kyoto University Graduate School of Medicine, JP) discusses the results of the STOPDAPT-2 ACS study. The aim of this study was to assess the safety of reducing dual antiplatelet therapy (DAPT) duration to 1-month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES) under the setting of acute coronary syndrome (ACS). The trial showed that in ACS… View more

Anticoagulation

Intervention
Job title: Interventional Cardiologist
Dr Joost Daemen is a senior interventional cardiologist at the Thorax Center, Erasmus MC, Rotterdam, NL. Dr Daemen obtained his degree in medicine at the Erasmus University Medical Center. He is actively involved in several drug-eluting stent trials and is Principal Investigator of four trials focusing on the safety and efficacy of renal sympathetic denervation in hypertension, heart failure,… View more
Health Literacy and Atrial Fibrillation
Author(s): Konstantinos N Aronis , Brittany Edgar , Wendy Lin , et al Added: 3 years ago
Atrial fibrillation (AF) requires complex management to prevent adverse outcomes. To succeed with AF, patients need to learn specialised medical terminology and the self-care skills and activation to interpret and report symptoms. AF care involves long-term adherence to medications with deleterious side-effects, such as antiarrhythmics and anticoagulants. The patient experience of AF is further… View more

Electrophysiology & Arrhythmia

Prevention & Chronic Conditions
Author(s): Freek WA Verheugt Added: 3 years ago
The yearly incidence of stroke in patients with atrial fibrillation (AF) is approximately 5%, which is five times higher than in comparable populations in sinus rhythm (SR). The stroke risk largely depends on the underlying heart disease. In 'lone' AF (absence of heart disease) the stroke risk is only 0.5% per year, whereas in AF associated with rheumatic valvular heart disease (VHD), like mitral… View more

Electrophysiology & Arrhythmia

Prevention & Chronic Conditions
ESC 23: The ONCO DVT Study
Author(s): Yugo Yamashita Added: 7 months ago
ESC 23 — In this concise interview, Dr Yugo Yamashita (Kyoto University Graduate School of Medicine, JP) reveals the findings of the ONCO DVT Study (NCT03895502). The ONCO DVT study (Takeshi Morimoto) aimed to determine the ideal duration of anticoagulation therapy with the direct oral anticoagulant (DOAC) edoxaban for the treatment of isolated distal deep vein thrombosis (IDDVT) in patients… View more

Anticoagulation

Vascular Disease and Surgery
Research Area(s) / Expertise: Job title: Professor of Cardiovascular Medicine
Prof Felicita Andreotti is a tenured Professor and Medical Director at the Gemelli IRCCS Hospital and Catholic University in Rome, Italy, where she currently coordinates cardiovascular research within the Scientific Directorate.Prof Andreotti gained her MD and two specialties - in respiratory and cardiac diseases - from the University of Strasbourg, France, and then Pisa, Italy. During her PhD… View more
Sotiris Antoniou, Consultant Pharmacist
Research Area(s) / Expertise:

Anticoagulation

Stroke Prevention in Atrial Fibrillation

 Job title: Consultant Pharmacist & Lead Cardiovascular Pharmacist
Mr Sotiris Antoniou is Consultant Pharmacist at Barts Heart Centre, part of Barts Health NHS Trust. Combined with his role as Lead Cardiovascular Pharmacist for UCL Partners supports medicines optimisation across the health economy to optimise patient outcomes and address unmet local needs. He is an independent prescriber and is currently chair of the cardiac committee for United Kingdom Clinical… View more